ABOUT CARDIUM: Historical Background
October 2005 - Acquired a portfolio of biologic growth factors from the Schering AG Group for potential use in treating ischemic and other cardiovascular conditions, including Generx®, a product candidate being developed for patients with chronic myocardial ischemia
March 2006 - Acquired technologies and products of InnerCool Therapies, Inc., a medical technology company in the emerging field of therapeutic hypothermia or patient temperature modulation
August 2006 - Acquired Tissue Repair Company, a company focused on the development of therapeutics for the potential treatment of chronic wounds and other tissue injuries, including our Excellagen® and Excellarate® product candidates
July 2009 - Sold InnerCool Therapies to Royal Philips Electronics (NYSE: PHG)
November 2010 - Launched the MedPodium® modern lifestyle product line, a portfolio of premium, science-based, easy to use nutraceuticals, metabolics and aesthetics designed to promote health and well-being.
January 2012 - Agreement for the sale and distribution of Excellagen® in South Korea
January 2012 - Initiated the ASPIRE clinical study at leading medical centers in Russia for Cardium's Generx® cardiovascular product candidate
March 2012 - Initiated U.S. market introduction of Excellagen® product for diabetic foot ulcers and other dermal wounds
October 2012 - Cardium acquired privately-held To Go Brands® to support the expansion of Cardium's health sciences nutraceutical brand platform